Health Care Services

Biodesix

Biodesix released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 37.98 M and EPS of USD -3.0789

Biodesix released FY2025 Q3 earnings on November 3 After-Market EST, actual revenue USD 21.77 M (forecast USD 20.98 M), actual EPS USD -1.1621 (forecast USD -1.506)

Biodesix to Release FY2025 Q3 Earnings on November 3 After-Market EST, Forecast Revenue USD 20.98 M, EPS USD -1.506

Biodesix Inc. Receives FDA Approval, Enhances NGS Diagnostic Capabilities

Biodesix released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 37.98 M, actual EPS USD -3.0847

Biodesix released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 20.02 M (forecast USD 18.47 M), actual EPS USD -0.08 (forecast USD -0.0683)

Biodesix to release FY2025 Q2 earnings on August 7 After-Market EST, forecast revenue USD 18.47 M, EPS USD -0.0683

Biodesix Launches First National CME-Certified Course on Lung Cancer Biomarkers

Biodesix Releases Latest Data from INSIGHT Study

Scotiabank Maintains Biodesix Rating, Reduces Price Target

Biodesix Inc. Participates in William Blair Growth Conference

FactSet: Biodesix Rated as Buy

TD Cowen lowers Biodesix Inc target price

Biodesix released FY2025 Q1 earnings on May 13 After-Market EST, actual revenue USD 17.96 M (forecast USD 19.5 M), actual EPS USD -0.0757 (forecast USD -0.07)

Chief Development Officer of Biodesix Inc. Disposes of Common Stock

Biodesix Reports 21% Revenue Growth in Q1 2025

Biodesix Inc expects a loss of 7 cents per share with 31.4% revenue growth

Biodesix to Release FY2025 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 19.5M, EPS USD -0.07

Canadian Investment Bank Maintains Biodesix Buy Rating with Lowered Target Price

Biodesix to Release Q1 2025 Financial Results

SMX Security Matters

Regencell Bioscience

Nuvve

Bristol-Myers Squibb Company

Innovative Eyewear

Monte Rosa Therapeutics

PELICAN ACQUISITION CORPORATION SHS USD0.0001(S/R 02/05/2030)

Century Therapeutics

Novabay Pharmac

Erasca

Cigna

BrightSpring Health Services - Unit

Labcorp

Quest Diagnostics

Hims & Hers Health

BrightSpring Health Services

Chemed

Option Care Health

GeneDx

CorVel

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Biodesix(BDSX.US)